Independent research and innovation platform. Not an NHS organisation or NHS-endorsed service.
Independent medicines intelligence

See where medication workflows lose information, medicines and capacity. Then watch Sitora close the loop.

Three interactive product experiences show the proposition more clearly than a report: reconcile medication changes across organisations, prevent avoidable repeat supply, and identify evidence-backed opportunities to release medicines-pathway capacity.

Clinical decisions remain with authorised professionals.Benefits are not claimed until verified.
One medicines intelligence programme

Three different failure modes. One verification discipline.

01

Detect

Identify a medication mismatch, avoidable supply signal or resource opportunity.

02

Explain

Show the source, provenance and evidence behind the signal.

03

Own

Route the next action to the organisation or professional responsible.

04

Close

Require acknowledgement, reconciliation or clinically governed implementation.

05

Verify

Record safety, financial effect and genuinely reusable capacity separately.

Evidence behind the proposition

The demos sit on evidence, not unsupported savings claims.

Inspect the evidence
2016£5bn / year opportunity

Unwarranted variation across acute hospitals

This was an efficiency opportunity, not £5 billion of cash proven to be wasted or recoverable today.
2020 review>4,000 WTE

Nursing capacity potentially released by ready-to-administer injectables

Modelled capacity release is not the same as reducing 4,000 posts or generating equivalent cash savings.
202516m appointments

GP appointments not attended

Missed appointments have many causes, including access barriers and health inequalities. They should not be framed simply as patient fault or all as avoidable.
Historic estimate, still cited in 2025/26~£300m / year

Unused medicines estimate still cited nationally

Do not present £300 million as a newly measured 2026 loss. The underlying national estimate is historic.
Evidence rule

Published NHS evidence can establish that a problem or intervention is real. It does not prove Sitora's local effect. That requires a governed pilot with observed outcomes and pre-agreed benefit definitions.

From demo to NHS evaluation

20 weeks to determine whether the opportunity is safely recoverable.

The next step is not a national rollout. It is a controlled pilot with baseline measurement, governed intervention and a Scale / Modify / Stop decision.

Commissioning principle

Net benefit, not headline savings.

Cash release, cost avoidance, capacity release and safety outcomes remain separate. Nothing enters a Resource Recovery Record merely because an algorithm identified an opportunity.

One medication view. Every authorised change owned. Every avoidable supply questioned. Every resource claim verified.